bioAffinity Technologies Files 8-K on Shareholder Vote
Ticker: BIAFW · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1712762
Sentiment: neutral
Topics: corporate-governance, shareholder-vote, filing-update
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K for a shareholder vote on 12/20. Expect updates soon.
AI Summary
bioAffinity Technologies, Inc. filed an 8-K on December 23, 2024, reporting on a matter submitted to a vote of security holders on December 20, 2024. The filing details the company's corporate structure and its principal executive offices located in San Antonio, Texas.
Why It Matters
This filing indicates a significant event where shareholders voted on company matters, which could impact future corporate decisions and strategy.
Risk Assessment
Risk Level: medium — Filings related to shareholder votes can signal significant corporate actions or changes that may affect the company's stock price.
Key Numbers
- 001-41463 — Commission File Number (Identifies the company's SEC filing history.)
- 46-5211056 — I.R.S. Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- December 20, 2024 (date) — Date of earliest event reported
- December 23, 2024 (date) — Date of report
- San Antonio, Texas (location) — Principal executive offices
FAQ
What specific matter was submitted to a vote of security holders on December 20, 2024?
The filing does not specify the exact matter voted upon, only that a submission to a vote of security holders occurred on December 20, 2024.
What is the principal executive office address for bioAffinity Technologies, Inc.?
The principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
When was this 8-K form filed with the SEC?
This 8-K form was filed as of December 23, 2024.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the fiscal year end for bioAffinity Technologies, Inc.?
The fiscal year end for the company is December 31.
Filing Stats: 753 words · 3 min read · ~3 pages · Grade level 11.9 · Accepted 2024-12-23 16:15:30
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 50KB
- 0001493152-24-051828.txt ( ) — 271KB
- biaf-20241220.xsd (EX-101.SCH) — 4KB
- biaf-20241220_def.xml (EX-101.DEF) — 29KB
- biaf-20241220_lab.xml (EX-101.LAB) — 36KB
- biaf-20241220_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 23, 2024 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer